Event Programme

Camargo Pharmaceutical Services – 505(b)(2) Used for the Approval of New Drugs

Format: PDF file | Document type: Event Programme

Camargo Pharmaceutical Services – 505(b)(2) Used for the Approval of New Drugs

Historically, the 505(b)(2) pathway is used for modifications of approved drugs. Yet, regulations state that a new chemical entity can also be approved under this FDA approval pathway. Camargo experts will discuss this process at the CHI: Drug Repositioning Summit, October 13-14, 2009. For more information, click here

Related resources from Camargo Pharmaceutical Services

Show more

Supplier info centre